Safety trial of high-intensity focused ultrasound therapy for pancreatic cancer

Table 3 Therapeutic effects

Rate of pain relief effect1 (%)	16/21 (66.7)
Rate of clinical benefit2 (%)	22/30 (73.3)
Rate of usefulness of evaluation after HIFU	22/30 (73.3)
using CE-US and/or CT/PET3 (%)
Rate of half reduction in CA19-9 level (%)	3/14 (21)
Mean tumor size (mm)	30.9 ± 1.7 SD
Efficacy of primary lesion (CR/PR/SD/PD)	0/4/22/4
Therapy after HIFU (operation/chemotherapy/radiation/BSC)	2/24/0/4
Adverse events4 (%)	3/30 (10)

¹“Effective” indicates a more than 30% improvement in pain relief;

²“Effective” was based on the patient’s declaration about appetite, fatigue, sleep, and weight. Pain: 16/21 (66.7%), appetite; 4/30 (13.3%), fatigue; 2/30 (6.7%), sleep; 8/30 (26.7%), weight; 2/30 (6.7%);

³CE-US: 18/30 (60%); CT: 10/30 (33%); MRI: 3/30 (10%); PET: 2/30 (6.7%);

⁴Pancreatic pseudocyst 2 cases → ECD and observed pancreatitis 1 case (after 2 wk and past history of pancreatitis). CE-US: Contrast-enhanced ultrasonography; HIFU: High-intensity focused ultrasound; CT: Computed tomography; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; BSC: Best supportive care; PET: Positron emission tomography.